Delivery Order SPE2DB22D2206-SPE2DB24FEH56
- Not listed
- This federal contract award, valued at $56,970.40, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a prescription medication, to support military healthcare programs. The contract is a Firm Fixed Price Delivery Order with a period of performance through February 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that...
- This federal contract award, valued at $6,305.24, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as...
- This federal contract award, valued at $23,598.71, was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026....
- This federal contract award, valued at $9,094.25, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product, to support the healthcare needs of military personnel, veterans, and other federal beneficiaries. This contract is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,542.83, is a Delivery Order for the pharmaceutical product XIFAXAN 550 MG TABLET 60S. The contract has an ultimate completion date of January 23, 2025 and is a Firm Fixed Price arrangement. The award is associated with a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds...
- This federal contract award, valued at $10,436.12, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XIFAXAN 550 mg tablets, a pharmaceutical product. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves...
- This federal contract award, valued at $27,156.27, was made by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a specialty pharmaceutical product. The award is a delivery order under Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a total potential value of $999,999,999.00...
- This federal contract award, valued at $24,685.34, was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The award is a Delivery Order under an Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary...
- This federal contract award, valued at $4,777.75, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XIFAXAN 550 mg tablets, a prescription medication used to treat certain gastrointestinal conditions. This contract is a delivery order under an Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support...
- This federal contract award, valued at $24,057.28, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for 60 tablets of the drug XIFAXAN 550 mg, with a performance period ending on May 8, 2025. The contract is a firm fixed-price, non-set-aside award, indicating open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB24FEH56Delivery Order
This federal contract award, valued at $20,613.61, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen's extensive federal contract awards demonstrate its role as a key vendor for federal healthcare programs, particularly within military and veterans' healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $20.6k | 11/27/23 |